The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | Positioning immunotherapies in the changing paradigm of myeloma treatment
Meral Beksac, MD, Ankara University, Ankara, Turkey, explores how to sequence immunotherapies in the evolving treatment landscape of multiple myeloma, including the use of anti-CD38 monoclonal antibodies at diagnosis which has shown to improve prognosis, as well as bi-specific antibodies, antibody-drug conjugates and CAR T-cells targeting BCMA. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
